Background
Plasmodium vivax represents a challenge to the public health system in the Americas with approximately 80 million people being exposed to this malaria agent and about 300,000 clinical cases registered in 2013 [
1]. Although the total number of confirmed malaria cases and deaths in the region has been decreased in the last decades,
P. vivax infections in Brazil still account for 42% of all cases and half of the deaths due to malaria registered in the Americas [
1]. Several potential challenges may impact the elimination efforts in Brazil where
P. vivax accounts for more than 80% of diagnosed malarial infections [
2] and cases of severe disease due to this species has been reported in the Amazon endemic region [
3‐
5]. Therefore, the development of an effective malaria vaccine is likely to contribute to a reduction of the disease burden in endemic populations. Notwithstanding the public health impact caused by
P. vivax, only a few vaccine candidates have been tested in clinical trials due to an unclear protective role of the potential vaccine targets (reviewed in [
6‐
8]).
Several studies have been performed in order to identify
P. vivax antigens as putative targets for vaccine development. The PvMSP-1, a 200 kDa protein highly expressed on the surface of merozoites, is one of the best-characterized antigens. This protein contains six highly polymorphic domains flanked by inter and intra-specific conserved sequences [
9]. Past studies on naturally acquired immune responses against PvMSP-1 variable regions showed several limitations. The most important is the focus of the analysis on recombinant proteins representing only one single version of the N-terminus of the protein. This is illustrated with examples: only two cohort studies in Brazil were able to show a reduced risk of infection and clinical protection associated to N-terminal PvMSP1-specific antibodies [
10,
11]. By contrast, a similar association between antibody responses to N-terminus of PvMSP-1 and either
P. vivax infection or asymptomatic status was not observed in another study conducted in Brazil and Papua New Guinea [
12]. This lack of consistency calls for an extended analysis where a broader representation of the PvMSP-1 repertoire must be included in further studies. With this in mind, Bastos and colleagues used a panel of different variants comprising three polymorphic PvMSP-1 domains (blocks 2, 6 and 10). They showed evidence for a positive correlation between cumulative exposure to malaria and presence and levels of IgG antibodies to many PvMSP-1 variant antigens [
13].
Whilst there is strong evidence showing that anti-PvMSP-1 antibodies are associated with cumulative exposure rather protection against vivax malaria, the relative contribution of different regions of the molecule inducing naturally acquired antibodies remains unknown. Therefore, a refined characterization of variant-specific immune response for different polymorphic domains of PvMSP-1 is required. Here the association of allele-specific humoral immune responses and clinical parameters, as well as the association of variant-specific antibodies to exposure, parasitaemia and age among non-complicated P. vivax patients were assessed. These antibody responses were also analysed in relation to the haemoglobin concentration aiming to expand current knowledge of the PvMSP-1 variant-specific immune response in exposed populations.
Discussion
MSP-1 has been considered one of the most promising molecules to be included in an anti-malarial subunit vaccine. However, its high allelic diversity observed in distinct
Plasmodium isolates [
16] might be one of the factors contributing to unsatisfactory results in the subsequent vaccine development. In fact, antigenic polymorphisms displayed by malaria parasites are considered as one of the strategies employed by them to escape from the host immune responses after recurrent infections [
17]. Here, naturally acquired antibodies were studied in
P. vivax infected patients from low and unstable malaria transmission settings. The results showed poor antigenicity of allelic variant antigens representing both block 2 and block 10 of PvMSP-1 in opposition to the high antigenicity of the conserved C-terminal, PvMSP-1
19. The high magnitude of IgG response to the conserved C-terminal domain of the PvMSP-1 protein that is the only fragment that remains attached to the merozoite surface during erythrocyte invasion [
18,
19] is an expected result and confirms previous data from several serological studies conducted in different epidemiological settings in the Brazilian endemic area [
20‐
26].
A weak recognition of the antigens representing variable domains of PvMSP-1 was described in this study. This result is in contrast with a higher degree of recognition of variant proteins of blocks 2 and 10 (91.3 and 100% for at least one variant antigen of each block, respectively) among 27 subjects who were infected with
P. vivax in a rural area in northwestern Brazil [
13]. This contrasting evidence can be explained by several factors such as differences in the age of the patients, in the transmission level and geographical location and, in the stage of infection or in the degree of past exposure of the sampled individuals. In this study, the total number of ‘seropositive’ antigens per individuals increases with the self-reported number of previous malaria episodes. Similarly, an association between allelic-specific IgG responses to block 10 of PvMSP-1 antigens and the time of residence in the endemic Amazonian region was previously reported [
13].
The seroprevalences concerning the BR07 version of both block 2 and block 10 were found to be higher as compared to other variant recognition. Indeed, this version was also found in relatively high frequency in infecting parasites based on sequencing of block 10 PvMSP-1 gene (32%). More importantly, there are 10 out of 13 (77%) patients carrying this specific haplotype that were seropositive against this recombinant protein. By contrast, Belem isolate has been previously reported as the predominant variant haplotype in a sample of
P. vivax parasites living in the Manaus municipality (one of the same areas studied here) based on block 2 of PvMSP-1 sequencing [
27]. In the present study, no sequencing of the block 2 of
PvMSP-
1 gene was performed. The respective serological data suggests a low seroprevalence for such antigen but it is unclear how this seroprevalence relates to the frequency of parasites bearing this specific haplotype.
The results showed a weak antigenicity of block 2 and block 10 variable domains. Such weak response is unlikely to be explained by the restricted panel of recombinant proteins used here. In fact, the set of antigens used to measure IgG responses among P. vivax infected patients would appear to be appropriate since approximated 60% of the amino acid sequences recovered were identical to those of the antigens used and being detected in 30 out of 41 local variant sequences. The most likely explanation is the small contribution of each haplotype to the circulating population. However, this explanation remains to be confirmed with a higher number of sequenced P. vivax parasites and a larger set of samples from exposed individuals.
Association between the specificity of circulating antibodies and variants of
P. falciparum infecting parasites has been extensively investigated in different endemic regions. No correlation between the allele-specific antibody response and variants of MSP-1 or MSP-2 circulating parasites were described in populations living in the Brazilian Amazon endemic region [
28,
29]. However, it is much less clear about the association between allelic specific antibodies and PvMSP-1 sequences found in circulating parasites. In fact, only a single work has demonstrated frequent mismatches between PvMSP-1 sequences in infecting parasites and the antigenic variants recognized by IgG antibodies in the Brazilian Amazon endemic region [
13].
Here, weak correlations between IgG responses were observed in pairs of variable antigens with high amino acid identity (>90%) contrasting data from that previous work conducted among 27 patients with acute
P. vivax infection living in Acre state [
13]. Therefore, the limited data available from PvMSP-1allele-specific antibodies undermined the possibility of discussing the deeper contribution of antigenic polymorphism on modulation of the naturally acquired immune response. In fact, even for vaccine based on PfMSP-1 which elicited antibodies that inhibited the growth of three diverse
P. falciparum isolates in vitro [
30] none protection against clinical malaria caused by diverse parasites in the field could be observed [
31].
A dual role for specific antibodies against
P. falciparum or
P. vivax infection has been suggested for both immunity and pathogenesis of malaria (reviewed in [
32]). Therefore, it was a reasonable hypothesis to investigate whether naturally acquired antibodies against conserved and variant PvMSP-1 proteins were associated with anaemia, a clinical parameter considered to be one of the major complications in
P. vivax infections. The results suggested that none of the antibody responses to variable block 10 was associated with the haemoglobin levels of the sampled patients. However, haemoglobin levels were negatively correlated with IgG antibody responses to four variant antigens of block 2 domain (BR07, BP29, BP39, and BEL). These results are in agreement with a previous study that showed an association with an increased risk of infection and antibodies to block 2 of MSP-1 of
P. falciparum [
33].
The association between anaemia and serology specific has been suggested for antibodies against to
P. falciparum rhoptry-associated proteins [
34,
35]. In relation to
P. vivax, parasitic antigens were detected on the surface of infected human RBCs [
36] and an association between specific antibodies to PvMSP
3 and anaemia has also been found [
14]. It is possible to speculate that, during the proteolytic processing, PvMSP-1 polypeptides representing block 2 and block 10 domains could bind to the surface of infected or non-infected erythrocytes, form immune-complexes and stimulate phagocytosis or complement-mediated lysis. However, the precise mechanism underlying the association between anaemia and the role of specific antibodies determining such haematological disorder during malarial infection is still elusive and out of the scope of the present study.
Levels of IgG antibodies against PvMSP-1
19 were found to be negatively associated with the haemoglobin levels. No statistically significant association was found between anaemia and the same antibodies. These two results might be explained by the IgG subclass distribution among serum samples from
P. vivax patients. In a previous study on the same sample, anti-PvMSP-1
19 non-cytophilic IgG2 and IgG4, as well as the cytophilic IgG3 antibodies, were detectable at similar proportions (approximately 50%) and levels [
14]. Such non-cytophilic antibodies may block protective mechanisms such as parasite killing in cooperation with blood monocytes (ADCI) for
P. falciparum [
37]. This rationale may be then extended to explain the associations between antibodies to block 2 variant antigens and anaemia. Notwithstanding the fact that this study did not intend to characterise the subclass immune response to variable domains of PvMSP-1, it is yet possible that among patients infected by
P. vivax who reported a short-term exposure to malaria transmission could present high proportions of non-cytophilic antibodies blocking any protective mechanism involved. In fact, block 2 domain of MSP-1 of
P. falciparum has been considered an important target of ADCI mechanism [
38]. However, the lack of an appropriate
P. vivax culture method and the difficulties involved in performing in vivo assays using this species limit the tools available to test this hypothesis.
Authors’ contributions
CGM, LCM and EMB conceived and designed the experiments; CGM and MFF performed the experiments; NS, CGM, LCM and EMB analysed the data; CJFF, MVGL, and EMB contributed reagents/materials/analysis tools; NS, CJD and EMB wrote the paper. All authors read and approved the final manuscript.